PT3247340T - Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas - Google Patents
Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicasInfo
- Publication number
- PT3247340T PT3247340T PT167034099T PT16703409T PT3247340T PT 3247340 T PT3247340 T PT 3247340T PT 167034099 T PT167034099 T PT 167034099T PT 16703409 T PT16703409 T PT 16703409T PT 3247340 T PT3247340 T PT 3247340T
- Authority
- PT
- Portugal
- Prior art keywords
- bdnf
- neuromuscular
- developmental
- neurodegenerative
- autoimmune
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 101150035467 BDNF gene Proteins 0.000 title 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 title 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 title 1
- 208000012239 Developmental disease Diseases 0.000 title 1
- 230000001363 autoimmune Effects 0.000 title 1
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 230000000626 neurodegenerative effect Effects 0.000 title 1
- 230000002232 neuromuscular Effects 0.000 title 1
- 208000018360 neuromuscular disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106365P | 2015-01-22 | 2015-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3247340T true PT3247340T (pt) | 2023-10-31 |
Family
ID=55310938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT167034099T PT3247340T (pt) | 2015-01-22 | 2016-01-21 | Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9763896B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3247340B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6951976B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102690198B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN116617195A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016209255B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112017015721A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2974092A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2961334T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1247101A1 (cg-RX-API-DMAC7.html) |
| MX (2) | MX392410B (cg-RX-API-DMAC7.html) |
| PT (1) | PT3247340T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016118741A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116617195A (zh) | 2015-01-22 | 2023-08-22 | 米托充制药公司 | 脑源性神经营养因子的诱导表达 |
| WO2018129258A1 (en) | 2017-01-06 | 2018-07-12 | Gencia Corporation | Novel phenyl derivatives |
| MX2019009038A (es) * | 2017-01-31 | 2019-12-09 | L Manfredi Paolo | D-metadona y sus derivados para uso en el tratamiento de trastornos del sistema nervioso. |
| EP3641743A2 (en) | 2017-06-23 | 2020-04-29 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20220044150A (ko) * | 2020-09-29 | 2022-04-06 | (주)세포바이오 | Manf를 포함하는 신경정신질환의 예방 또는 치료용 조성물 |
| WO2023205625A2 (en) * | 2022-04-18 | 2023-10-26 | Mitochon Pharmaceuticals, Inc. | 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases |
| WO2025051360A1 (en) * | 2023-09-06 | 2025-03-13 | Instituto de Medicina Molecular João Lobo Antunes | Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1764095A1 (en) * | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| EP2170338A2 (en) * | 2007-07-06 | 2010-04-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dna-pkcs modulates energy regulation and brain function |
| JP6706204B2 (ja) | 2013-08-30 | 2020-06-03 | イエール ユニバーシティ | 新規２，４−ジニトロフェノール製剤およびその使用法 |
| CN116617195A (zh) * | 2015-01-22 | 2023-08-22 | 米托充制药公司 | 脑源性神经营养因子的诱导表达 |
-
2016
- 2016-01-21 CN CN202211548767.9A patent/CN116617195A/zh active Pending
- 2016-01-21 CA CA2974092A patent/CA2974092A1/en active Pending
- 2016-01-21 KR KR1020177023034A patent/KR102690198B1/ko active Active
- 2016-01-21 EP EP16703409.9A patent/EP3247340B1/en active Active
- 2016-01-21 ES ES16703409T patent/ES2961334T3/es active Active
- 2016-01-21 MX MX2017009402A patent/MX392410B/es unknown
- 2016-01-21 PT PT167034099T patent/PT3247340T/pt unknown
- 2016-01-21 JP JP2017539363A patent/JP6951976B2/ja active Active
- 2016-01-21 AU AU2016209255A patent/AU2016209255B2/en active Active
- 2016-01-21 WO PCT/US2016/014312 patent/WO2016118741A1/en not_active Ceased
- 2016-01-21 US US15/002,531 patent/US9763896B2/en active Active
- 2016-01-21 CN CN201680017379.4A patent/CN107405315A/zh active Pending
- 2016-01-21 BR BR112017015721A patent/BR112017015721A2/pt not_active Application Discontinuation
- 2016-01-21 EP EP23188878.5A patent/EP4306167B1/en active Active
- 2016-01-21 HK HK18106712.4A patent/HK1247101A1/zh unknown
- 2016-11-21 US US15/357,412 patent/US9974755B2/en active Active
-
2017
- 2017-07-18 MX MX2022005937A patent/MX2022005937A/es unknown
- 2017-09-18 US US15/707,239 patent/US10220006B2/en active Active
-
2019
- 2019-01-17 US US16/250,470 patent/US10864173B2/en active Active
-
2020
- 2020-11-09 US US17/093,193 patent/US11717497B2/en active Active
-
2021
- 2021-03-01 JP JP2021031635A patent/JP7440092B2/ja active Active
- 2021-09-27 AU AU2021240120A patent/AU2021240120A1/en not_active Abandoned
-
2022
- 2022-10-03 JP JP2022159466A patent/JP2022173519A/ja active Pending
-
2023
- 2023-06-16 US US18/336,440 patent/US20240156750A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3247340T (pt) | Expressão induzida de fator neurotrófico derivado de cérebro (bdnf) para o tratamento de doenças neuromusculares, neurodegenerativas, autoimunes, do desenvolvimento e/ou metabólicas | |
| IL282655A (en) | Methods of treating developmental disorders using pipradrol | |
| IL259281B (en) | History of bipyrazolyl used in the treatment of autoimmune diseases | |
| IL269106A (en) | Methods for the treatment of neurodegenerative diseases | |
| PL3419622T3 (pl) | Leczenie neurodegeneracyjnej choroby oczu przy użyciu pridopidyny | |
| PT3393579T (pt) | Sistema de tratamento ocular | |
| GB201516905D0 (en) | Treatment of Neurodegenerative diseases | |
| IL269604A (en) | Pentides for the treatment of autoimmune diseases | |
| IL254155A0 (en) | pain treatment | |
| SMT202400277T1 (it) | Trattamento di disturbi metabolici con varianti di fgf21 | |
| GB201714307D0 (en) | Treatment of neurodegenerative diseases | |
| ZA202002910B (en) | Treatment of skin disorders | |
| EP3271017A4 (en) | Treatment of skin conditions | |
| GB201601456D0 (en) | Improvements relating to retinal treatment | |
| GB201714311D0 (en) | Treatment of neurodegenerative diseases | |
| GB201714303D0 (en) | Treatment of neurodegenerative diseases | |
| GB201710109D0 (en) | Albumin-based therapeutic molecules | |
| GB201710105D0 (en) | Albumin-based therapeutic molecules | |
| GB201704666D0 (en) | Treatment of neurodegenerative diseases | |
| GB201514909D0 (en) | Treatment of autoimmune diseases | |
| GB201703768D0 (en) | Skin treatment methods | |
| GB201703734D0 (en) | Skin treatment methods | |
| EP3116507A4 (en) | Treatment of brain and central nervous system tumors | |
| GB201522257D0 (en) | Treatment of autism | |
| GB201506944D0 (en) | Therapeutic treatment |